76 related articles for article (PubMed ID: 30848481)
21. Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review.
Klajer E; Garnier L; Goujon M; Schlurmann-Constans F; Mery B; Nguyen Tan Hon T; Mouillet G; Calcagno F; Thiery-Vuillemin A
Semin Oncol; 2020; 47(2-3):103-116. PubMed ID: 32522380
[TBL] [Abstract][Full Text] [Related]
22. Integrated multi-omics data analyses for exploring the co-occurring and mutually exclusive gene alteration events in colorectal cancer.
Zhou Y; Cheng X; Zhang F; Chen Q; Chen X; Shen Y; Lai C; Kota VG; Sun W; Huang Q; Yuan Y; Wang J; Lai M; Zhang D
Hum Mutat; 2020 Sep; 41(9):1588-1599. PubMed ID: 32485022
[TBL] [Abstract][Full Text] [Related]
23.
Tan KT; Yeh CN; Chang YC; Cheng JH; Fang WL; Yeh YC; Wang YC; Hsu DS; Wu CE; Lai JI; Chang PM; Chen MH; Lu ML; Chen SJ; Chao Y; Hsiao M; Chen MH
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32238472
[TBL] [Abstract][Full Text] [Related]
24. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
Rassy E; Flippot R; Albiges L
Ther Adv Med Oncol; 2020; 12():1758835920907504. PubMed ID: 32215057
[TBL] [Abstract][Full Text] [Related]
26. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
27. Nesprin-1 impact on tumorigenic cell phenotypes.
Sur-Erdem I; Hussain MS; Asif M; Pınarbası N; Aksu AC; Noegel AA
Mol Biol Rep; 2020 Feb; 47(2):921-934. PubMed ID: 31741263
[TBL] [Abstract][Full Text] [Related]
28. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
[TBL] [Abstract][Full Text] [Related]
29. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
Ito K
Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
[TBL] [Abstract][Full Text] [Related]
31. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract][Full Text] [Related]
32. The role of RNA-modifying proteins in renal cell carcinoma.
Alhammadi MA; Bajbouj K; Talaat IM; Hamoudi R
Cell Death Dis; 2024 Mar; 15(3):227. PubMed ID: 38503745
[TBL] [Abstract][Full Text] [Related]
33. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract][Full Text] [Related]
34. A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.
Knudsen S; Hansen A; Foegh M; Petersen S; Mekonnen H; Jia L; Shah P; Martin V; Frykman G; Pili R
PLoS One; 2023; 18(8):e0290681. PubMed ID: 37647320
[TBL] [Abstract][Full Text] [Related]
35. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract][Full Text] [Related]
36. Cystic Clear Cell Renal Cell Carcinoma: A Morphological and Molecular Reappraisal.
Pini GM; Lucianò R; Colecchia M
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444462
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy.
Garrett ME; Soldano KL; Erwin KN; Zhang Y; Gordeuk VR; Gladwin MT; Telen MJ; Ashley-Koch AE
Blood Adv; 2023 Sep; 7(17):4782-4793. PubMed ID: 36399516
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of fifteen hub genes to identify a promising diagnostic model, regulated networks, and immune cell infiltration in acute kidney injury.
Sun T; Cao Y; Huang T; Sang Y; Dai Y; Tao Z
J Clin Lab Anal; 2022 Nov; 36(11):e24709. PubMed ID: 36125921
[TBL] [Abstract][Full Text] [Related]
39. Identification of key genes of the ccRCC subtype with poor prognosis.
Puzanov GA
Sci Rep; 2022 Aug; 12(1):14588. PubMed ID: 36028558
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway.
Zhen Z; Shen Z; Sun P
Bioengineered; 2022 Apr; 13(4):9467-9481. PubMed ID: 35389768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
